NeuroOne Medical Technologies (NASDAQ:NMTC) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of NeuroOne Medical Technologies (NASDAQ:NMTC) to a sell rating in a report released on Saturday.

Separately, Zacks Research raised NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NeuroOne Medical Technologies currently has an average rating of “Moderate Buy” and an average target price of $2.23.

NeuroOne Medical Technologies Stock Down 4.0%

NeuroOne Medical Technologies stock opened at $0.68 on Friday. NeuroOne Medical Technologies has a twelve month low of $0.40 and a twelve month high of $1.18. The firm has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.80. The company has a market capitalization of $34.36 million, a PE ratio of -4.00 and a beta of 0.71.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm had revenue of $2.89 million for the quarter, compared to analysts’ expectations of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several hedge funds have recently made changes to their positions in the company. Focus Financial Network Inc. bought a new position in NeuroOne Medical Technologies in the third quarter worth $31,000. Warberg Asset Management LLC bought a new stake in shares of NeuroOne Medical Technologies during the 2nd quarter valued at $27,000. Legato Capital Management LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 4th quarter worth about $34,000. Squarepoint Ops LLC bought a new position in shares of NeuroOne Medical Technologies in the 4th quarter worth about $36,000. Finally, Susquehanna International Group LLP bought a new position in shares of NeuroOne Medical Technologies in the 3rd quarter worth about $47,000. 16.07% of the stock is currently owned by institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.